Dai Wenbin, Long Longhai, Wang Xiaoqiang, Li Sen, Xu Houping
Geriatric Department, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan, China.
Spinal Surgery Department, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan, China.
Chin Med. 2022 Apr 28;17(1):53. doi: 10.1186/s13020-022-00611-w.
Inflammatory bowel disease (IBD) is a collective term for inflammatory diseases including Crohn's disease and ulcerative colitis. Toll-like receptor 4 (TLR4) is thought to play a key role in the pathogenesis of IBD. Inhibition of TLR4 has been recognized as an effective target for the treatment of IBD. Many phytochemicals have been shown to have potential as new drugs for the treatment of IBD. This review surveyed the available literature and reports which focused on the in vivo effects of phytochemicals targeting TLR4 in different models of IBD, and clarified the significance of TLR4 as a current therapeutic target for IBD. Based on our review, we have concluded that phytochemicals targeting TLR4 are potentially effective candidates for developing new therapeutic drugs against IBD.
炎症性肠病（IBD）是包括克罗恩病和溃疡性结肠炎在内的炎症性疾病的统称。Toll样受体4（TLR4）被认为在IBD的发病机制中起关键作用。抑制TLR4已被公认为是治疗IBD的有效靶点。许多植物化学物质已显示出作为治疗IBD新药的潜力。本综述调查了现有文献和报告，这些文献和报告聚焦于植物化学物质在不同IBD模型中对TLR4的体内作用，并阐明了TLR4作为IBD当前治疗靶点的重要性。基于我们的综述，我们得出结论，靶向TLR4的植物化学物质可能是开发抗IBD新治疗药物的有效候选物。
